Relief of Moderate to Severe Acute Pain

This medication is applied in clinical settings requiring supportive relief for high-intensity pain when symptoms are resistant to typical symptom management. It is relevant across domains, including acute discomfort experienced postoperatively after surgery, pain resulting from injury, and severe localized pain such as certain types of migraines or acute dental pain. It helps provide supportive symptomatic assistance when symptoms create noticeable interference with daily stability. The medication is indicated for the management of severe acute and chronic pain and for fever not responding to other treatments. It is also applied across domains where additional symptomatic support is needed.

---

Management of Spasm-Related Pain (Colic)

Analgin Srbolek is commonly used in conditions where symptoms involve intense pain linked to the spasm or involuntary contraction of smooth muscles. This cluster of symptoms is characteristic of colic, specifically episodes linked to organ-specific functional stress. It contributes to improved comfort during difficult, cramping episodes, supporting the overall symptom load.

---

Control of Persistent High Fever

The drug is used in situations involving symptomatic discomfort due to persistent high fever that is not adequately lowered by conventional antipyretics. It is applied when temperature becomes a significant clinical concern during acute illness. This action supports improved comfort and assists with maintaining a sense of stability during phases where the patient experiences heightened, refractory febrile symptoms. The main symptomatic domains addressed include high-intensity pain, spastic discomfort, and persistent febrile symptoms.

---

Quick Fact

Quick Fact: Relief for Spastic Pain

Regulatory References

1. European Medicines Agency Assessment Report

Who Can and Cannot Use Analgin Srbolek?

Analgin Srbolek, which contains the active ingredient Metamizole, is subject to strict regulatory rules that define who is eligible to use the medicine and who is prohibited from doing so.

---

Absolute Contraindications (Must Not Use)

The medicine is contraindicated in several specific populations, as mandated by official regulatory documentation. This includes any patient with a documented history of agranulocytosis or hypersensitivity to Metamizole or other pyrazolone derivatives. Use is also prohibited in individuals with impaired bone marrow function or known diseases of the haematopoietic system. Furthermore, patients diagnosed with analgesic-induced asthma syndrome, acute intermittent hepatic porphyria, or genetic glucose-6-phosphate dehydrogenase (G6PD) deficiency must not use the medicine.

Age, Pregnancy, and Organ Function

The pediatric population is restricted, as the medicine is contraindicated in infants below 3 months of age or those with a body weight under 5 kg. For the elderly population, a dose reduction is recommended. Analgin Srbolek is strictly contraindicated during the third trimester of pregnancy and is contraindicated while breastfeeding.

Patients with severe renal or hepatic impairment are cautioned, and long-term use is not recommended in these groups.

Interactions with other medicines and products

Metamizole, the active ingredient in Analgin Srbolek, has formally documented interaction patterns primarily involving drug-metabolizing enzymes and pharmacodynamic effects, as described in regulatory documentation.

Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Interaction Outcome
Pharmacokinetic Induction	Substrates of CYP3A4, CYP2B6, CYP2C19 (e.g., Cyclosporine, Bupropion, Efavirenz, Methadone, Tacrolimus, Valproate)	Metamizole acts as a moderate to strong enzyme inducer, resulting in decreased plasma concentrations and potential reduced efficacy of the co-administered drug.
Pharmacodynamic Interference	Acetylsalicylic Acid (low-dose anti-thrombotic)	The active metabolite of Metamizole is documented to inhibit the effect on platelet aggregation, which may counteract the anti-thrombotic action.
Haematological Risk	Medicines that cause agranulocytosis (e.g., Methotrexate)	Increased risk of haematotoxicity and augmentation of a potentially serious adverse reaction.
Substance Interaction	Alcohol	Co-consumption is restricted as Metamizole may potentiate the effects of alcohol.

These patterns structure the official regulatory profile. Caution is required in the elderly due to the potential for prolonged metabolite elimination, which may increase the severity of interactions with nephrotoxic co-medications. The profile establishes the official constraints on co-administration with these medicinal products and substances.

Central Multimodal Pain Modulation

Analgin Srbolek's active metabolites rapidly enter the Central Nervous System (CNS) to modulate pain signaling across multiple systems. This mechanism involves the inhibition of the central enzyme COX-3 and the activation of receptors within the opioidergic and endocannabinoid ( CB1) pathways. This multi-target approach modulates the conductance of ascending nociceptive signals and facilitates activity within the descending pain-inhibitory pathways.

Hypothalamic Set Point and Core Temperature Regulation

The drug acts directly on the hypothalamus, the brain's thermoregulatory center. By reducing the central synthesis of fever-inducing prostaglandins ( PGE2), the drug efficiently lowers the elevated temperature set point. This physiological adjustment facilitates the initiation of heat-dissipation mechanisms; the physiological consequence is the abatement of the febrile state.

Visceral Smooth Muscle Relaxation

The drug exerts a distinct spasmolytic effect by interfering with the cellular signaling responsible for muscle contraction, specifically by inhibiting Inositol Phosphate synthesis. This action reduces the release of intracellular calcium ( Ca^2+) needed for sustained contraction, resulting in the relaxation of involuntary smooth muscle fibers within visceral tissue. This mechanism alters the baseline contractile tension of smooth muscle.

Official Administration Guidelines

Analgin Srbolek, which contains the active substance Metamizole, is administered via three primary routes: oral (using tablets or solutions), intramuscular (IM), and intravenous (IV) injection. Its use is intended for short-term treatment only.

Dosing and Frequency

The standardized adult single dose for oral administration is up to 1,000 mg (1 gram). The maximum total dose taken orally must not exceed 4,000 mg (4 grams) per day. When administered via injection, the total daily dose should not exceed 5,000 mg. Dosing is typically applied on an as-needed (PRN) basis to manage acute symptoms, with a required interval of at least 6 to 8 hours between successive doses, up to a maximum of four times daily.

Administration Specifics

Oral tablets must be swallowed whole and not crushed to ensure correct delivery. It is generally recommended to take the oral form after meals. For the injectable solution, especially via the intravenous route, administration must be performed very slowly. Standard requirements mandate that the lowest dose necessary to control symptoms is used.

Population-Specific Rules

Dosage for pediatric patients (le 14 years) is calculated based on body weight, typically 8–16 mg/kg for a single dose. Fixed-strength tablets are not suitable for children under 10 years due to the necessary precision in weight-based dosing. Patients with pre-existing hepatic or renal impairment generally require a lower dose due to the potential for prolonged drug excretion.

Research Evidence / Overview of Studies for Analgin Srbolek

The evidence base for Analgin Srbolek (Metamizole) is compiled from research, including Randomized Controlled Trials (RCTs) and Systematic Reviews published in peer-reviewed literature that explore how symptoms change over time in observed populations. Research describes patterns related to how patients reported their experiences with acute physical discomfort and systemic imbalance. This overview summarizes what was observed in studies for the medicine's main uses.

Evidence for Use in Acute Severe Pain

Research has examined Analgin Srbolek for conditions involving periods of heightened symptom activity; research included studies following surgical procedures or injury. The research included short-term RCTs where the medicine was evaluated against both placebo and other established non-opioid pain relievers. Findings describe patterns observed in the studies, where single-dose administration was associated with measurements meeting a predefined pain relief threshold compared to placebo over observation periods of four to six hours. Comparative research also explored whether the reported short-term changes measured during the study period were non-inferior or comparable to those seen with certain other non-opioid analgesics. Research provides insight into short-term changes for high-intensity discomfort.

Evidence for Use in Managing Spasm-Related Pain and Fever

The medicine was studied for conditions characterized by fluctuating or episodic manifestations; research included studies of acute visceral pain linked to the involuntary contraction of smooth muscles. The medicine was evaluated in studies observing responses over defined time intervals for persistent high fever that was observed in patients unresponsive to less potent treatments. Research in children describes patterns where the observed reduction in body temperature was studied in comparison with other antipyretics, particularly in the short-term. However, data for this use in general adult fever populations are limited.

Long-Term Studies and Follow-Up Data

The majority of the evidence is derived from research exploring short-term symptom changes over defined time intervals. Follow-up durations in the most widely cited RCTs were limited to assessments over hours or, at most, short-term periods of less than two weeks. Research has also explored its use in conditions involving chronic pain; studies examined outcomes related to daily functioning and the required dose of opioid medication in populations with cancer-related pain. Data for extended use or long-term outcomes are still emerging, and there is limited information for outcomes measured over periods exceeding a few weeks.

Key Studies & References

1. European Medicines Agency Assessment Report for Metamizole

Common questions about Analgin Srbolek (FAQ)

---

Q: Is Analgin Srbolek the same as regular metamizole?

Analgin Srbolek is a specific brand name for the medicine whose active substance is Metamizole. Therefore, Analgin Srbolek contains the same primary drug ingredient as generic or other brand-name Metamizole products.

---

Q: What is the biggest difference between Analgin Srbolek and ibuprofen?

Analgin Srbolek (Metamizole) is classified as a non-opioid pain reliever and fever reducer that also has a specific spasmolytic (muscle relaxing) property. This mechanism of action differs from traditional Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen, which are primarily anti-inflammatory. Official information notes that Metamizole has weak anti-inflammatory effects.

---

Q: Why is Analgin Srbolek popular in some countries but restricted in others?

The use of Metamizole is regulated differently across the world. While it is widely available in many countries for severe pain and fever, it is restricted or prohibited in others, such as the U.S. and U.K. This difference is primarily due to the rare but serious documented risk of a blood condition called agranulocytosis.

---

Q: Can Analgin Srbolek be used for dental pain relief?

The medicine is officially indicated for the treatment of acute severe pain following injuries or surgeries, and for acute or severe pain symptoms in general. This broad regulatory indication may apply to various sources of acute severe pain, which could include severe dental pain.

---

Q: Is there a known interaction between Analgin Srbolek and blood thinners?

Yes, official regulatory documents state that Metamizole is documented to inhibit the anti-thrombotic effect of low-dose acetylsalicylic acid (Aspirin). This interaction may reduce the effectiveness of the blood-thinning action of low-dose acetylsalicylic acid.

---

Q: Can Analgin Srbolek be taken alongside paracetamol (acetaminophen)?

Regulatory data on interactions suggests that Metamizole may reduce the rate at which Paracetamol (Acetaminophen) is removed from the body. This could potentially lead to higher levels of Paracetamol in the bloodstream. It is important to review the combination of Metamizole and Paracetamol with a healthcare professional.

---

Q: Is it normal to feel a bit drowsy after taking Analgin Srbolek?

Drowsiness, dizziness, and headaches are noted as known potential side effects in some official product information. Due to the possibility of these effects, caution may be necessary when performing tasks that require full attention.

---

Q: What evidence exists to support the use of Analgin Srbolek for colic pain?

Regulatory indications specifically list colic as one of the conditions for which Metamizole is used. Its unique spasmolytic property, which helps relax involuntary smooth muscle, is the key mechanism that supports its use for pain related to colic.

---

Q: Are there specific medical conditions that absolutely prohibit taking Analgin Srbolek?

Yes, regulatory information lists several absolute prohibitions (contraindications). These include a documented history of agranulocytosis, bone marrow suppression, hypersensitivity to Metamizole, analgesic-induced asthma, or genetic conditions like G6PD deficiency and acute intermittent hepatic porphyria.

---

Q: Is there a link between Analgin Srbolek and liver function issues?

Official adverse reaction listings include Drug-Induced Liver Injury (DILI) as a possible serious adverse reaction that may occur, ranging from a few days to months after beginning treatment. Patients with severe existing liver impairment generally require dose adjustment.

---

Q: Does Analgin Srbolek have any effect on blood pressure?

Yes, regulatory data lists hypotension (low blood pressure) as an uncommon potential side effect. This risk is noted to be higher in older adults or patients with pre-existing circulatory instability.

---

Q: What should I look out for if I'm taking Analgin Srbolek with other strong painkillers?

The primary regulatory concern when combining with other strong pain medicines is the increased risk of blood-related toxicity (haematotoxicity). This risk is particularly noted when combined with drugs that also affect bone marrow function, such as Methotrexate.

---

Q: How does the pain relief quality of Analgin Srbolek compare to aspirin?

Research summarized in product literature indicates that Metamizole is a potent analgesic effective for acute severe pain. Some studies have reported patterns suggesting that its pain relief duration may be longer when compared to acetylsalicylic acid (Aspirin).

---

Q: Why is Analgin Srbolek sometimes used for post-operative pain?

The medicine is indicated for acute severe pain after surgeries. Its strong analgesic, antipyretic, and spasmolytic properties provide a robust, non-opioid option for pain management after an operation.

---

Q: Is it safe to drive after taking Analgin Srbolek?

Official patient information cautions that side effects may include dizziness or drowsiness, which could affect a person's ability to drive or safely operate machinery. If side effects such as dizziness or drowsiness occur, operating a vehicle or machinery should be avoided.

---

Q: Can Analgin Srbolek cause changes in urine color?

Yes, official product information lists a change to a pink or reddish urine color as a known potential side effect. This change is generally understood to be caused by a metabolite of the drug. However, any unusual physical change should be reviewed by a healthcare professional.

---

Q: Is Analgin Srbolek ever used to treat chronic pain conditions?

The official regulatory indication is for the short-term treatment of acute severe pain and high fever. While some research has investigated its effects in chronic conditions like cancer-related pain, long-term use is not routinely recommended in the regulatory product information.

---

Q: Does Analgin Srbolek interact with herbal supplements like St. John's Wort?

Metamizole interacts with certain liver enzymes (CYP3A4) responsible for drug metabolism. St. John's Wort is known to stimulate these same enzymes and could potentially decrease the concentration and effectiveness of Metamizole in the bloodstream.

---

Q: What kind of research has been done on Analgin Srbolek's use in children (if allowed)?

Regulatory research summaries mention studies observing its use for fever reduction in children when compared with other fever reducers. However, use in children is restricted by strict weight-based dosing guidelines and contraindications for very young infants.

Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of Analgin Srbolek (Metamizole) to ensure product stability and safety.

Requirement Area	Official Constraints
Temperature and Light	Store the medicine, particularly the injection solution, not above 25 C and keep in the original package for protection from light. Freezing the injectable solution is prohibited.
Stability and Packaging	Use of the product is prohibited after the expiry date shown on the carton. The medicine must remain in its original packaging until use.
Child Safety	A universal regulatory mandate requires that Analgin Srbolek be stored out of the sight and reach of children at all times.
Disposal Rules	Do not dispose of unused or expired medicine via wastewater or household waste. Consult a pharmacist for instructions on discarding the product according to local pharmaceutical waste collection requirements.